282 related articles for article (PubMed ID: 34526064)
41. Role of klotho on antidepressant and antisuicidal effects of low-dose ketamine infusion among patients with treatment-resistant depression and suicidal ideation.
Chen MH; Bai YM; Wu HJ; Li CT; Lin WC; Tsai SJ; Su TP; Tu PC
J Affect Disord; 2023 Nov; 340():471-475. PubMed ID: 37579883
[TBL] [Abstract][Full Text] [Related]
42. The effectiveness of repeated intravenous ketamine on subjective and objective psychosocial function in patients with treatment-resistant depression and suicidal ideation.
Zhou Y; Wang C; Lan X; Zheng W; Li H; Chao Z; McIntyre RS; Ning Y
J Affect Disord; 2022 May; 304():78-84. PubMed ID: 35176337
[TBL] [Abstract][Full Text] [Related]
43. Hippocampal volume changes after (R,S)-ketamine administration in patients with major depressive disorder and healthy volunteers.
Evans JW; Graves MC; Nugent AC; Zarate CA
Sci Rep; 2024 Feb; 14(1):4538. PubMed ID: 38402253
[TBL] [Abstract][Full Text] [Related]
44. Use of Ketamine in Elderly Patients with Treatment-Resistant Depression.
Medeiros da Frota Ribeiro C; Riva-Posse P
Curr Psychiatry Rep; 2017 Nov; 19(12):107. PubMed ID: 29138992
[TBL] [Abstract][Full Text] [Related]
45. Ketamine and Attentional Bias Toward Emotional Faces: Dynamic Causal Modeling of Magnetoencephalographic Connectivity in Treatment-Resistant Depression.
Gilbert JR; Galiano CS; Nugent AC; Zarate CA
Front Psychiatry; 2021; 12():673159. PubMed ID: 34220581
[TBL] [Abstract][Full Text] [Related]
46. The effects of low-dose ketamine on the prefrontal cortex and amygdala in treatment-resistant depression: A randomized controlled study.
Li CT; Chen MH; Lin WC; Hong CJ; Yang BH; Liu RS; Tu PC; Su TP
Hum Brain Mapp; 2016 Mar; 37(3):1080-90. PubMed ID: 26821769
[TBL] [Abstract][Full Text] [Related]
47. D-serine plasma concentration is a potential biomarker of (R,S)-ketamine antidepressant response in subjects with treatment-resistant depression.
Moaddel R; Luckenbaugh DA; Xie Y; Villaseñor A; Brutsche NE; Machado-Vieira R; Ramamoorthy A; Lorenzo MP; Garcia A; Bernier M; Torjman MC; Barbas C; Zarate CA; Wainer IW
Psychopharmacology (Berl); 2015 Jan; 232(2):399-409. PubMed ID: 25056852
[TBL] [Abstract][Full Text] [Related]
48. Ketamine's rapid antisuicidal effects are not attenuated by Buprenorphine.
Hosanagar A; Schmale A; LeBlanc A
J Affect Disord; 2021 Mar; 282():252-254. PubMed ID: 33418374
[TBL] [Abstract][Full Text] [Related]
49. Neurocognitive effects of six ketamine infusions and the association with antidepressant response in patients with unipolar and bipolar depression.
Zhou Y; Zheng W; Liu W; Wang C; Zhan Y; Li H; Chen L; Li M; Ning Y
J Psychopharmacol; 2018 Oct; 32(10):1118-1126. PubMed ID: 30260273
[TBL] [Abstract][Full Text] [Related]
50. Cognitive Behavioral Therapy to Sustain the Antidepressant Effects of Ketamine in Treatment-Resistant Depression: A Randomized Clinical Trial.
Wilkinson ST; Rhee TG; Joormann J; Webler R; Ortiz Lopez M; Kitay B; Fasula M; Elder C; Fenton L; Sanacora G
Psychother Psychosom; 2021; 90(5):318-327. PubMed ID: 34186531
[TBL] [Abstract][Full Text] [Related]
51. Studying pre-treatment and ketamine-induced changes in white matter microstructure in the context of ketamine's antidepressant effects.
Sydnor VJ; Lyall AE; Cetin-Karayumak S; Cheung JC; Felicione JM; Akeju O; Shenton ME; Deckersbach T; Ionescu DF; Pasternak O; Cusin C; Kubicki M
Transl Psychiatry; 2020 Dec; 10(1):432. PubMed ID: 33319774
[TBL] [Abstract][Full Text] [Related]
52. Pre-treatment Pain Symptoms Influence Antidepressant Response to Ketamine in Depressive Patients.
Lan X; Zhou Y; Wang C; Li W; Zhang F; Liu H; Fu L; Wu K; McIntyre RS; Ning Y
Front Psychiatry; 2022; 13():793677. PubMed ID: 35370832
[TBL] [Abstract][Full Text] [Related]
53. The effect of esketamine in patients with treatment-resistant depression with and without comorbid anxiety symptoms or disorder.
Daly EJ; Turkoz I; Salvadore G; Fedgchin M; Ionescu DF; Starr HL; Borentain S; Trivedi MH; Thase ME; Singh JB
Depress Anxiety; 2021 Nov; 38(11):1120-1130. PubMed ID: 34293233
[TBL] [Abstract][Full Text] [Related]
54. Ketamine augmentation for outpatients with treatment-resistant depression: Preliminary evidence for two-step intravenous dose escalation.
Cusin C; Ionescu DF; Pavone KJ; Akeju O; Cassano P; Taylor N; Eikermann M; Durham K; Swee MB; Chang T; Dording C; Soskin D; Kelley J; Mischoulon D; Brown EN; Fava M
Aust N Z J Psychiatry; 2017 Jan; 51(1):55-64. PubMed ID: 26893373
[TBL] [Abstract][Full Text] [Related]
55. Ketamine for depression.
Jelen LA; Stone JM
Int Rev Psychiatry; 2021 May; 33(3):207-228. PubMed ID: 33569971
[TBL] [Abstract][Full Text] [Related]
56. Change in neurocognitive functioning in patients with treatment-resistant depression with serial intravenous ketamine infusions: The Bio-K multicenter trial.
Singh B; Parikh SV; Voort JLV; Pazdernik VK; Achtyes ED; Goes FS; Yocum AK; Nykamp L; Becerra A; Smart L; Greden JF; Bobo WV; Frye MA; Burdick KE; Ryan KA
Psychiatry Res; 2024 May; 335():115829. PubMed ID: 38479192
[TBL] [Abstract][Full Text] [Related]
57. Can 'floating' predict treatment response to ketamine? Data from three randomized trials of individuals with treatment-resistant depression.
Acevedo-Diaz EE; Cavanaugh GW; Greenstein D; Kraus C; Kadriu B; Park L; Zarate CA
J Psychiatr Res; 2020 Nov; 130():280-285. PubMed ID: 32861983
[TBL] [Abstract][Full Text] [Related]
58. The effects of ketamine and classic hallucinogens on neurotrophic and inflammatory markers in unipolar treatment-resistant depression: a systematic review of clinical trials.
Rossi GN; Hallak JEC; Baker G; Dursun SM; Dos Santos RG
Eur Arch Psychiatry Clin Neurosci; 2023 Feb; 273(1):129-155. PubMed ID: 35829812
[TBL] [Abstract][Full Text] [Related]
59. Relationship between hippocampal volume and inflammatory markers following six infusions of ketamine in major depressive disorder.
Zhou YL; Wu FC; Wang CY; Zheng W; Lan XF; Deng XR; Ning YP
J Affect Disord; 2020 Nov; 276():608-615. PubMed ID: 32871692
[TBL] [Abstract][Full Text] [Related]
60. The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence.
McIntyre RS; Rodrigues NB; Lee Y; Lipsitz O; Subramaniapillai M; Gill H; Nasri F; Majeed A; Lui LMW; Senyk O; Phan L; Carvalho IP; Siegel A; Mansur RB; Brietzke E; Kratiuk K; Arekapudi AK; Abrishami A; Chau EH; Szpejda W; Rosenblat JD
J Affect Disord; 2020 Sep; 274():903-910. PubMed ID: 32664031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
